Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study

BACKGROUND: Ipragliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubules. SGLT2 inhibitors are expected to be effective in patients with insulin resistance and obesity, but it is important to select treatment according to pat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Med Res
Hlavní autoři: Iemitsu, Kotaro, Iizuka, Takashi, Takihata, Masahiro, Takai, Masahiko, Nakajima, Shigeru, Minami, Nobuaki, Umezawa, Shinichi, Kanamori, Akira, Takeda, Hiroshi, Kawata, Takehiro, Ito, Shogo, Kikuchi, Taisuke, Amemiya, Hikaru, Kaneshiro, Mizuki, Mokubo, Atsuko, Takuma, Tetsuro, Machimura, Hideo, Tanaka, Keiji, Asakura, Taro, Kubota, Akira, Aoyagi, Sachio, Hoshino, Kazuhiko, Ishikawa, Masashi, Obana, Mitsuo, Sasai, Nobuo, Kaneshige, Hideaki, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro
Médium: Artigo
Jazyk:Inglês
Vydáno: Elmer Press 2016
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4817576/
https://ncbi.nlm.nih.gov/pubmed/27081422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2492w
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky